Bridging the Unbridgeable: The Promise of PROTACs in Drug Discovery
Imagine a world where diseases once deemed “undruggable” are met with targeted, precise therapies. This vision is rapidly becoming a reality, thanks to the revolutionary technology of PROTACs (proteolysis-targeting chimeras).
Elevating Patient Safety: Syngene’s Leadership in Nitrosamine Testing and Comprehensive Analytical Development Services
The pharmaceutical industry has been forced to reckon with the increasing discovery of nitrosamine impurities in drugs, compounds known for their carcinogenic potential. This became especially pronounced in 2018, when several widely used medications, such as Valsartan and Ranitidine, were recalled due to the presence of nitrosamines.
4x the Performance, Zero Compromise: How Functionalized Polymers Are Changing the Rules
In the race to decarbonize the global economy, advanced materials are no longer a luxury – they’re a necessity. The global specialty polymer market, valued at over $87 billion globally (2024), is fast becoming the backbone of innovations in clean energy, medical devices, and high-performance electronics.
Forging the Future: Why Strategic Outsourcing in Biologics is No Longer Optional, It’s Essential for Success
The biologics revolution is in full swing, and as innovation accelerates, so does the complexity of bringing these life-changing therapies to market. With the BIO International Convention on the horizon, the corridors will be buzzing with talk of groundbreaking science.
Paws, Pills and Progress – CRDMO’s pivotal role
As I stepped into the conference hall in Boston, I overheard an investor say, “The next billion-dollar biotech might just come from the animal health sector.
SynWeave™: Revolutionizing Biopharma Manufacturing by Improving Titer, Timelines and Manufacturability
Since the establishment of Chinese Hamster Ovary (CHO) cells in the 1950s, the production of therapeutic proteins has seen continuous innovation and growth. The potential of therapeutic proteins, such as antibodies, bispecifics, antibody-drug conjugates (ADCs), and recombinant proteins, is driving the demand for high-titer clones.
Harnessing the Power of Upstream Platform Integration to Accelerate Biopharma Innovation
The biopharmaceutical industry has been a hotbed of innovation in recent years, with an increasing number of novel recombinant protein therapeutics receiving the U.S. Food and Drug Administration’s (FDA) green light.
The Future of Therapeutics: Syngene Leading the Charge with Targeted Protein Degradation Platform
In this exclusive interview Kenneth Barr, SVP of Discovery Research at Syngene International, sheds light on how Syngene is uniquely positioned to lead the targeted protein degradation revolution in drug discovery.
The $100 Billion Frontier: Untapped Potential in Animal Health Innovation
The global animal health market is a staggering $60 billion industry, projected to reach $100 billion by 2030. This phenomenal growth reflects a confluence of factors: rising pet ownership (especially companion animals), increasing protein demand, reducing gaseous emissions, and the ever-present threat of zoonotic diseases.
Advancing mAb manufacturing with customer-centric solutions
Monoclonal antibodies (mAbs) have become a cornerstone in modern therapeutics, offering targeted treatment options across various diseases, including cancer, autoimmune disorders, and infectious diseases.